Written By | Health News Agencies
HEALTH
For families living with type 3 Gaucher disease, the cruelest part has always been watching the treatment work and fail at the same time.
Every two weeks, patients sit through an intravenous infusion that keeps the disease's assault on their liver, spleen, blood and bones in check. But the drug cannot get into the brain. So even as the body stabilizes, the mind and nerves can keep slipping: unsteady walking, trembling coordination, slurred speech, fading memory.
On Wednesday, November 18, 2026, the U.S. Food and Drug Administration approved a medicine designed to break through that wall.
The drug is venglustat, sold under the brand name Infilbray by Genzyme, a Sanofi company. It is a once-daily oral tablet and the first therapy ever approved specifically to treat the neurological manifestations of type 3 Gaucher disease, also known as GD3.
"This drug's ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms," said Kyle Diamantas, the FDA's acting commissioner.
A Disease Hiding in Plain Sight
Gaucher disease is a rare, inherited lysosomal storage disorder. People with it carry mutations in a gene called GBA1, which leaves them short of an enzyme called glucocerebrosidase. Without enough of that enzyme, fatty substances known as glycosphingolipids pile up inside cells instead of being broken down and recycled.
In the body, that toxic buildup causes an enlarged liver and spleen, anemia, low platelet counts that lead to easy bruising and bleeding, and painful bone disease.
Most people with Gaucher disease have type 1, which largely spares the brain. Type 3 is different. It is a chronic neuronopathic form, meaning the brain and nervous system are also under attack, usually progressing over years. Patients can develop progressive problems with balance, coordination, speech, memory and thinking. In its most serious course, the disease can lead to dementia and loss of muscle control.
Gaucher disease as a whole is rare, and type 3 is only a small slice of it, which helps explain why patients waited so long for a treatment aimed squarely at their brains.
Why the Old Drugs Couldn't Help
Since the 1990s, the backbone of Gaucher care has been enzyme replacement therapy, or ERT, which delivers a working copy of the missing enzyme by IV drip. Sanofi's own Cerezyme, known generically as imiglucerase, is one of the best known. In January 2026, the FDA expanded Cerezyme's label to cover the non-neurological symptoms of type 3 disease.
But enzyme replacement has a fatal flaw for GD3 patients. The enzyme is a large protein molecule that cannot cross the blood-brain barrier, the tight biological filter that shields the brain from much of what circulates in the blood. ERT has not shown benefit for cognition or eye-movement problems in these patients.
Pills that work a different way, called substrate reduction therapies, have not filled the gap either. One, eliglustat, is kept out of the brain. Another, miglustat, proved ineffective for neurological symptoms.
"The neurological manifestations remained beyond the reach of available therapies," said Dr. Pramod Mistry, director of the Yale Lysosomal Disease Center and Gaucher Disease Treatment Center.
How Infilbray Works
Venglustat takes a different route. Rather than replacing the missing enzyme, it is a brain-penetrant inhibitor of glucosylceramide synthase, the enzyme that makes the fatty substance in the first place. Turn down the tap, and less waste accumulates. Crucially, venglustat is small enough to get into the central nervous system.
Early evidence that this approach could work came from a phase 2 study called LEAP. In that open-label trial, 11 adults with GD3 took venglustat 15 mg once a day on top of their regular imiglucerase infusions for a year.
The results, published in the journal Brain in 2023, showed the drug was crossing into the brain and doing its job there. Median levels of glucosylceramide in the cerebrospinal fluid fell by 81 percent, and glucosylsphingosine dropped by 70 percent. Nine of the 11 patients improved on a modified scale measuring ataxia, the loss of coordination that is a hallmark of the disease. Investigators were cautious, noting that an uncontrolled study needed confirmation in a properly controlled trial.
The Head-to-Head Trial That Won Approval
That confirmation came from LEAP2MONO, a phase 3 trial that took the unusual step of pitting the new pill directly against the existing standard.
The randomized, double-blind, double-dummy study enrolled 43 patients aged 12 and older with GD3. All had already received enzyme replacement for at least three years and had reached treatment goals for their body-wide disease. Twenty-one were assigned to once-daily venglustat alone, and 22 to imiglucerase infusions every two weeks, for 52 weeks. Thanks to the double-dummy design, every patient took both a pill and an infusion, with one of them a placebo, so neither patients nor doctors knew who was getting what.
The main goal combined two measures into a single prespecified global test: change on the four-item modified SARA, a scale that rates ataxia, and the total score on RBANS, a battery that tests memory, attention, language and other thinking skills.
Venglustat beat imiglucerase on that combined measure with statistical significance, with a p-value of 0.0137. Neither Sanofi nor the FDA has released detailed point estimates for each component, according to NeurologyLive. Pharmacy Times reported, citing Sanofi's February 2026 topline announcement, that venglustat also met three of four key secondary goals, covering spleen volume, liver volume and hemoglobin, holding systemic disease at levels approximating those achieved with ERT.
An open-label extension of the study is continuing.
The Side Effects to Know
Infilbray is not without risks, and its label carries warnings for suicidal ideation and behavior, for lens opacification (clouding of the eye's lens) in children, and for harm to an unborn baby. The latter two were identified in animal studies.
In the 52-week trial, side effects that showed up more often with venglustat than with imiglucerase included diarrhea (14 percent versus 0 percent), an enlarged spleen (14 percent versus 0 percent), nausea (14 percent versus 5 percent), depression (10 percent versus 0 percent), gastroenteritis (10 percent versus 0 percent) and vomiting (10 percent versus 5 percent), as reported by NeurologyLive.
Overall, the most common problems fell into two buckets: digestive upsets and mood-related effects. Patients and families will want to watch closely for changes in mood and to discuss eye checks for children.
Fast-Tracked From Start to Finish
The FDA gave venglustat nearly every acceleration it has. The drug held orphan drug designation, fast track designation for GD3, and Priority Review, which shortens the agency's review clock.
"This approval reflects the FDA's commitment to advancing therapeutic options for patients with rare diseases," Diamantas said.
The approval covers adults and children who weigh at least 15 kilograms, about 33 pounds.
It is part of a cluster of rare-disease approvals the FDA has issued this month, as regulators increasingly lean on smaller, carefully designed trials for conditions that affect too few people for traditional mega-studies.
The drug has had setbacks elsewhere. In an earlier phase 2 study called MOVES-PD, venglustat failed to beat placebo in Parkinson's disease linked to GBA1 mutations, a reminder that a mechanism that helps one condition does not automatically help another.
Expert Perspective
For specialists who have spent their careers managing what they could not fix, the approval is a landmark.
Dr. Mistry, of Yale, called it one that "represents a major milestone for patients, families, and the global type 3 Gaucher disease community."
Sanofi's head of research and development, Houman Ashrafian, said when the phase 3 results first emerged in February that "a daily pill could make a serious difference" for patients facing neurological challenges.
There are also practical wins. A once-daily tablet could, for the right patients, replace the grind of IV infusions every two weeks, freeing families from repeated trips to clinics and infusion centers.
Some questions remain open. The pivotal trial was small, as rare-disease trials usually are, and detailed component results have not been made public. Longer follow-up from the extension study will show whether the neurological benefits hold or grow over years, and how the safety warnings play out in everyday use. Pricing has not been disclosed in reports on the approval.
What This Means for You
If you or your child has type 3 Gaucher disease: talk to your Gaucher specialist about whether Infilbray is right for you. The approval covers adults and children who weigh at least 15 kilograms (33 pounds). Do not stop or change any current treatment without medical advice.
Ask about monitoring. Because the label warns about suicidal thoughts and behavior, families should know the warning signs of depression and mood change. Ask your doctor about eye exams for children, given the lens-clouding warning seen in animal studies.
Pregnancy planning matters. The drug carries a warning for embryo-fetal toxicity, so anyone who could become pregnant should discuss contraception and family planning with their care team.
If you live outside the U.S.: Sanofi says venglustat is still under regulatory review for type 3 Gaucher disease in Europe and Japan, with submissions planned in other markets in the coming year.
Know your genetics. Gaucher disease is inherited. Families with a history of the condition can ask about genetic counseling and testing.
The Bottom Line
For years, type 3 Gaucher patients have lived with a split verdict: a body kept in check and a brain left to fend for itself. Infilbray is the first approved medicine designed to close that gap, a daily pill that slips past the blood-brain barrier to attack the buildup at its source.
It will not be the right answer for everyone, and its warnings demand careful follow-up. But in a disease where the neurological damage was long considered untreatable, a door that was locked for decades has finally opened.